In the US, it is competing in the METex14-positive NSCLC market with Novartis/Incyte's rival MET inhibitor Tabrecta (capmatinib). The EAMS opinion is based on results from the phase 2 VISION study ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...